Loan terms

RooLife Group (ASX:RLG) and AFT Pharmaceuticals (ASX:AFP) launch online over-the-counter drugs in China – The Market Herald

Subscribe

Be the first with news that moves the market

  • RooLife Group (RLG) and AFT Pharmaceuticals (AFP) launch a line of OTC drugs online in China
  • The drugs will be available on the Kiwi Health Global Flagship Store which launched in 2020 with an initial range of health supplement trials from AFT
  • Notably, the store has become New Zealand’s first OTC direct-to-consumer online drug marketplace in China.
  • Under the partnership, RooLife provides its digital marketing and in-store operation, while AFT provides its products, including Vitamin C&D Lipo sachets and Kiwisoothe.
  • At market close, RooLife was up 20% and trading at 1.2 cents, while AFT was up 8.45% and trading at $3.85 per share.

RooLife Group (RLG) and AFT Pharmaceuticals (AFP) have launched a range of over-the-counter (OTC) drugs online in China.

The drugs will be available on the Kiwi Health Global Flagship Store which launched in 2020 with an initial trial line of health supplements from AFT.

Following its registration under China’s OTC Cross-Border E-Commerce (CBEC) Pilot Program, the store has become New Zealand’s first direct-to-consumer online drug marketplace in China.

“The Kiwi Health Global Flagship Store provides a significant growth opportunity for AFT. We are delighted to be the first New Zealand company to be approved for the CBEC OTC pilot program which was launched in 2019,” commented AFT Founder and Chief Executive Dr Hartely Atkinson.

“The Kiwi Health Global Flagship Store aims to capitalize on the high awareness of the AFT product line, the high esteem and demand for New Zealand products in China, and the low number of OTC products approved on Tmall Global. “

As part of the partnership, RooLife provides its digital marketing and in-store operation, while AFT provides its products, including Vitamin C&D Lipo sachets, Ferro sachet, Crystawash Extend and Kiwisoothe.

As part of the launch, the over-the-counter drug portfolio will continue to be expanded with AFT’s painkillers along with five other products.

“This partnership with AFT Pharmaceuticals puts us at the forefront of the market, directly addressing the strong demand for international OTC pharmaceuticals from Chinese consumers,” said RooLife CEO Bryan Carr.

“This collaboration leverages our expertise in the Chinese market and e-commerce, including our role in managing and obtaining the necessary approvals for the sale of OTC pharmaceutical products in China, combined with AFT’s extensive pharmaceutical experience and to its popular product line.

At market close, RooLife was up 20% and trading at 1.2 cents, while AFT was up 8.45% and trading at $3.85 per share.